Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2017

Open Access 01-12-2017 | Research

Social/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain

Authors: Julio López-Bastida, Luz María Peña-Longobardo, Isaac Aranda-Reneo, Eduardo Tizzano, Mark Sefton, Juan Oliva-Moreno

Published in: Orphanet Journal of Rare Diseases | Issue 1/2017

Login to get access

Abstract

Background

The aim of this study was to determine the economic burden and health-related quality of life (HRQOL) of patients with Spinal Muscular Atrophy (SMA) and their caregivers in Spain.

Methods

This was a cross-sectional and retrospective study of patients diagnosed with SMA in Spain. We adopted a bottom up, prevalence approach design to study patients with SMA. The patient’s caregivers completed an anonymous questionnaire regarding their socio-demographic characteristics, use of healthcare services and non-healthcare services. Costs were estimated from a societal perspective (including healthcare costs and non-healthcare costs), and health-related quality of life (HRQOL) was assessed using the EQ-5D questionnaire. The main caregivers also answered a questionnaire on their characteristics and on their HRQOL.

Results

A total of 81 caregivers of patients with different subtypes of SMA completed the questionnaire. Based on the reference unitary prices for 2014, the average annual costs per patient were € 33,721. Direct healthcare costs were € 10,882 (representing around 32.3% of the total cost) and the direct non-healthcare costs were € 22,839 (67.7% of the total cost). The mean EQ-5D social tariff score for patients was 0.16, and the mean score of the EQ-5D visual analogue scale was 54. The mean EQ-5D social tariff score for caregivers was 0.49 and their mean score on the EQ-5D visual analogue scale was 69.

Conclusion

The results highlight the burden that SMA has in terms of costs and decreased HRQOL, not only for patients but also for their caregivers. In particular, the substantial social/economic burden is mostly attributable to the high direct non-healthcare costs.
Literature
1.
go back to reference Pearn J. Classification of spinal muscular atrophies. Lancet. 1980;1(8174):919–22. Pearn J. Classification of spinal muscular atrophies. Lancet. 1980;1(8174):919–22.
2.
go back to reference Alías L, Barceló MJ, Bernal S, Martínez-Hernández R, Also-Rallo E, Vázquez C, Santana A, Millán JM, Baiget M, Tizzano EF. Improving detection and genetic counseling in carriers of spinal muscular atrophy with two copies of the SMN1 gene. Clin Genet. 2014;85:470–5.CrossRefPubMed Alías L, Barceló MJ, Bernal S, Martínez-Hernández R, Also-Rallo E, Vázquez C, Santana A, Millán JM, Baiget M, Tizzano EF. Improving detection and genetic counseling in carriers of spinal muscular atrophy with two copies of the SMN1 gene. Clin Genet. 2014;85:470–5.CrossRefPubMed
3.
go back to reference López-Bastida J, Oliva-Moreno J, Linertová R, Serrano-Aguilar P. Social/economic costs and health-related quality of life in patients with rare diseases in Europe. Eur J Health Econ. 2016;17(Suppl 1):1–5.CrossRefPubMed López-Bastida J, Oliva-Moreno J, Linertová R, Serrano-Aguilar P. Social/economic costs and health-related quality of life in patients with rare diseases in Europe. Eur J Health Econ. 2016;17(Suppl 1):1–5.CrossRefPubMed
4.
go back to reference Klug C, Schreiber-Katz O, Thiele S, Schorling E, Zowe J, Reilich P, Walter MC, Nagels KH. Disease burden of spinal muscular atrophy in Germany. Orphanet J Rare Dis. 2016 May 4;11(1):58.CrossRefPubMedPubMedCentral Klug C, Schreiber-Katz O, Thiele S, Schorling E, Zowe J, Reilich P, Walter MC, Nagels KH. Disease burden of spinal muscular atrophy in Germany. Orphanet J Rare Dis. 2016 May 4;11(1):58.CrossRefPubMedPubMedCentral
5.
go back to reference von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–7.CrossRef von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–7.CrossRef
6.
7.
go back to reference Zerres K, Rudnik-Schoneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52:518–23.CrossRefPubMed Zerres K, Rudnik-Schoneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52:518–23.CrossRefPubMed
8.
go back to reference Finkel RS, McDermott MP, Kaufmann P, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014 Aug 26;83(9):810–7.CrossRefPubMedPubMedCentral Finkel RS, McDermott MP, Kaufmann P, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014 Aug 26;83(9):810–7.CrossRefPubMedPubMedCentral
10.
go back to reference Lopez-Bastida J, Serrano-Aguilar P, Perestelo-Perez L, Oliva-Moreno J. Social-economic costs and quality of life of Alzheimer disease in the Canary Islands. Spain Neurology. 2006;67(12):2186–91.CrossRefPubMed Lopez-Bastida J, Serrano-Aguilar P, Perestelo-Perez L, Oliva-Moreno J. Social-economic costs and quality of life of Alzheimer disease in the Canary Islands. Spain Neurology. 2006;67(12):2186–91.CrossRefPubMed
11.
go back to reference Lopez-Bastida J, Monton-Alvarez F, Serrano-Aguilar P, Perestelo-Perez L, et al. Mov Disord. 2008;23:212–7.CrossRefPubMed Lopez-Bastida J, Monton-Alvarez F, Serrano-Aguilar P, Perestelo-Perez L, et al. Mov Disord. 2008;23:212–7.CrossRefPubMed
12.
go back to reference López-Bastida J, Perestelo-Pérez L, Montón-Alvarez F, Serrano-Aguilar P, Alfonso-Sanchez JL. Social economic costs and health-related quality of life in patients with amyotrophic lateral sclerosis in Spain. Amyotroph Lateral Scler. 2009 Aug;10(4):237–43.CrossRefPubMed López-Bastida J, Perestelo-Pérez L, Montón-Alvarez F, Serrano-Aguilar P, Alfonso-Sanchez JL. Social economic costs and health-related quality of life in patients with amyotrophic lateral sclerosis in Spain. Amyotroph Lateral Scler. 2009 Aug;10(4):237–43.CrossRefPubMed
13.
go back to reference López-Bastida J, Linertová R, Oliva-Moreno J, Posada-de-la-Paz M, Serrano-Aguilar P. Social economic costs and health-related quality of life in patients with systemic sclerosis in Spain. Arthritis Care Res. 2014;66(3):473–80.CrossRef López-Bastida J, Linertová R, Oliva-Moreno J, Posada-de-la-Paz M, Serrano-Aguilar P. Social economic costs and health-related quality of life in patients with systemic sclerosis in Spain. Arthritis Care Res. 2014;66(3):473–80.CrossRef
18.
go back to reference Hoefman RJ, van Exel J, Brouwer W. How to include informal care in economic evaluations. PharmacoEconomics. 2013;31:1105–19.CrossRefPubMed Hoefman RJ, van Exel J, Brouwer W. How to include informal care in economic evaluations. PharmacoEconomics. 2013;31:1105–19.CrossRefPubMed
19.
go back to reference van den Berg B, Spauwen P. Measurement of informal care: an empirical study into the valid measurement of time spent on informal caregiving. Health Econ. 2006;15:447–60.CrossRefPubMed van den Berg B, Spauwen P. Measurement of informal care: an empirical study into the valid measurement of time spent on informal caregiving. Health Econ. 2006;15:447–60.CrossRefPubMed
20.
go back to reference van den Berg B, Brouwer W, van Exel J, Koopmanschap M, van den Bos G, Rutten F. Economic valuation of informal care: lessons from the application of the opportunity costs and proxy good methods. Soc Sci Med. 2006;62:835–45.CrossRefPubMed van den Berg B, Brouwer W, van Exel J, Koopmanschap M, van den Bos G, Rutten F. Economic valuation of informal care: lessons from the application of the opportunity costs and proxy good methods. Soc Sci Med. 2006;62:835–45.CrossRefPubMed
21.
go back to reference López-Bastida J, Linertová R, Oliva-Moreno J, Posada-de-la-Paz M, Serrano-Aguilar P, Kanavos P, Taruscio D, Schieppati A, Iskrov G, Baji P, Delgado C, von der Schulenburg JM, Persson U, Chevreul K, Fattore G; BURQOL-RD Research Network. Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe. Eur J Health Econ. 2016;17(Suppl 1):99–108. López-Bastida J, Linertová R, Oliva-Moreno J, Posada-de-la-Paz M, Serrano-Aguilar P, Kanavos P, Taruscio D, Schieppati A, Iskrov G, Baji P, Delgado C, von der Schulenburg JM, Persson U, Chevreul K, Fattore G; BURQOL-RD Research Network. Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe. Eur J Health Econ. 2016;17(Suppl 1):99–108. 
23.
go back to reference Drummond MF, O’Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press; 1997. Drummond MF, O’Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press; 1997.
24.
25.
go back to reference Stolk EA, Busschbach JJ, Vogels T, et al. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2000;9:29–38.CrossRef Stolk EA, Busschbach JJ, Vogels T, et al. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2000;9:29–38.CrossRef
26.
go back to reference Willems DCM, Joore MA, Nieman FHM, Severens JL, Wouters EFM, Hendriks JJE. Using EQ-5D in children with asthma, rheumatic disorders, diabetes, and speech/language and/or hearing disorders. Int J Technol Assess Health Care. 2009;25:391–9.CrossRefPubMed Willems DCM, Joore MA, Nieman FHM, Severens JL, Wouters EFM, Hendriks JJE. Using EQ-5D in children with asthma, rheumatic disorders, diabetes, and speech/language and/or hearing disorders. Int J Technol Assess Health Care. 2009;25:391–9.CrossRefPubMed
27.
go back to reference Secnik K, Matza LS, Cottrell S, Edgell E, Tilden D, Mannix S. Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United kingdom. Med Decis Mak. 2005;25:56–70.CrossRef Secnik K, Matza LS, Cottrell S, Edgell E, Tilden D, Mannix S. Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United kingdom. Med Decis Mak. 2005;25:56–70.CrossRef
28.
go back to reference Matza LS, Secnik K, Mannix S, Sallee FR. Parent-proxy EQ-5D ratings of children with attention-deficit hyperactivity disorder in the US and the UK. PharmacoEconomics. 2005;23(8):777–90.CrossRefPubMed Matza LS, Secnik K, Mannix S, Sallee FR. Parent-proxy EQ-5D ratings of children with attention-deficit hyperactivity disorder in the US and the UK. PharmacoEconomics. 2005;23(8):777–90.CrossRefPubMed
29.
go back to reference Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. Md State Med. 1965;14:61–5. Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. Md State Med. 1965;14:61–5.
30.
go back to reference Shah S, Vanclay F, Cooper B. Improving the sensitivity of the Barthel index for stroke rehabilitation. J Clin Epidemiol. 1989;42:703–9.CrossRefPubMed Shah S, Vanclay F, Cooper B. Improving the sensitivity of the Barthel index for stroke rehabilitation. J Clin Epidemiol. 1989;42:703–9.CrossRefPubMed
31.
go back to reference Ruzafa CJ, Damian Moreno J. Valoracion de la discapacidad fisica: el Indice de Barthel. Rev Esp Salud Pública. 1997;71:127–37.CrossRef Ruzafa CJ, Damian Moreno J. Valoracion de la discapacidad fisica: el Indice de Barthel. Rev Esp Salud Pública. 1997;71:127–37.CrossRef
32.
go back to reference Hérbert R, Bravo G, Préville M. Reliability, validity, and reference values of the Zarit burden interview for assessing informal caregivers of community-dwelling older persons with dementia. Can JAging. 2000:494–507. Hérbert R, Bravo G, Préville M. Reliability, validity, and reference values of the Zarit burden interview for assessing informal caregivers of community-dwelling older persons with dementia. Can JAging. 2000:494–507.
33.
go back to reference Vázquez LA, López-Bastida J, Perez-Nieves M, Oliva-Moreno J, Villoro R, Dilla T, Merino M, Sapin H, Aranda I, Reviriego J, López-Siguero JP. Impact of glycemic control and diabetic complications or comorbidities on health related quality of life in pediatric patients with type 1 diabetes mellitus and their caregivers in Spain. Valencia: 42nd Annual Conference of the International Society for Pediatric and Adolescent Diabetes; 2016. ISPAD 2016 October 26 – 29 Vázquez LA, López-Bastida J, Perez-Nieves M, Oliva-Moreno J, Villoro R, Dilla T, Merino M, Sapin H, Aranda I, Reviriego J, López-Siguero JP. Impact of glycemic control and diabetic complications or comorbidities on health related quality of life in pediatric patients with type 1 diabetes mellitus and their caregivers in Spain. Valencia: 42nd Annual Conference of the International Society for Pediatric and Adolescent Diabetes; 2016. ISPAD 2016 October 26 – 29
34.
go back to reference Oliva-Moreno J, Lopez-Bastida J, Worbes-Cerezo M, Serrano-Aguilar P. Health related quality of life of Canary Islands citizens: combining a general health survey and observational studies. BMC Public Health. 2010;10:675–83.CrossRefPubMedPubMedCentral Oliva-Moreno J, Lopez-Bastida J, Worbes-Cerezo M, Serrano-Aguilar P. Health related quality of life of Canary Islands citizens: combining a general health survey and observational studies. BMC Public Health. 2010;10:675–83.CrossRefPubMedPubMedCentral
35.
go back to reference Alvarez-Sabín J, Quintana M, Masjuan J, Oliva-Moreno J, Mar J, Gonzalez-Rojas N, Becerra V, Torres C, Yebenes M. CONOCES investigators group. Economic impact of patients admitted to stroke units in Spain: Eur J Health Econ. 2017;18(4):449–458. Alvarez-Sabín J, Quintana M, Masjuan J, Oliva-Moreno J, Mar J, Gonzalez-Rojas N, Becerra V, Torres C, Yebenes M. CONOCES investigators group. Economic impact of patients admitted to stroke units in Spain: Eur J Health Econ. 2017;18(4):449–458.
36.
go back to reference Delgado JF, Oliva J, Llano M, Pascual-Figal D, Grillo JJ, Comín-Colet J, Díaz B, Martínez de La Concha L, Martí B, Peña LM. Health care and non-health care costs in the treatment of patients with symptomatic chronic heart failure in Spain. Rev Esp Cardiol (Engl Ed). 2014;67(8):643–50.CrossRef Delgado JF, Oliva J, Llano M, Pascual-Figal D, Grillo JJ, Comín-Colet J, Díaz B, Martínez de La Concha L, Martí B, Peña LM. Health care and non-health care costs in the treatment of patients with symptomatic chronic heart failure in Spain. Rev Esp Cardiol (Engl Ed). 2014;67(8):643–50.CrossRef
37.
go back to reference Trapero-Bertran M, Oliva J. Economic burden of HIV/AIDS in the European context. Heal Econ Rev. 2014;4:15.CrossRef Trapero-Bertran M, Oliva J. Economic burden of HIV/AIDS in the European context. Heal Econ Rev. 2014;4:15.CrossRef
38.
go back to reference Chevreul K, Gandré C, Brigham KB, López-Bastida J, Linertová R, Oliva-Moreno J, Serrano-Aguilar P, Posada-de-la-Paz M, Taruscio D, Schieppati A, Iskrov G, Gulácsi L, von der Schulenburg JM, Kanavos P, Persson U, Fattore G. BURQOL-RD research network. Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe. Eur J Health Econ. 2016;17(Suppl 1):43–52.CrossRefPubMed Chevreul K, Gandré C, Brigham KB, López-Bastida J, Linertová R, Oliva-Moreno J, Serrano-Aguilar P, Posada-de-la-Paz M, Taruscio D, Schieppati A, Iskrov G, Gulácsi L, von der Schulenburg JM, Kanavos P, Persson U, Fattore G. BURQOL-RD research network. Social/economic costs and health-related quality of life in patients with fragile X syndrome in Europe. Eur J Health Econ. 2016;17(Suppl 1):43–52.CrossRefPubMed
39.
go back to reference Cavazza M, Kodra Y, Armeni P, De Santis M, López-Bastida J, Linertová R, Oliva-Moreno J, Serrano-Aguilar P, Posada-de-la-Paz M, Taruscio D, Schieppati A, Iskrov G, Péntek M, von der Schulenburg JM, Kanavos P, Chevreul K, Persson U, Fattore G, et al. Eur J Health Econ. 2016;17(Suppl 1):19–29.CrossRefPubMed Cavazza M, Kodra Y, Armeni P, De Santis M, López-Bastida J, Linertová R, Oliva-Moreno J, Serrano-Aguilar P, Posada-de-la-Paz M, Taruscio D, Schieppati A, Iskrov G, Péntek M, von der Schulenburg JM, Kanavos P, Chevreul K, Persson U, Fattore G, et al. Eur J Health Econ. 2016;17(Suppl 1):19–29.CrossRefPubMed
40.
go back to reference Kind P, Klose K, Gusi N, Olivares PR, Greiner W. Can adult weights be used to value child health states? Testing the influence of perspective in valuing EQ-5D-Y. Qual Life Res. 2015;24:2519–39.CrossRefPubMedPubMedCentral Kind P, Klose K, Gusi N, Olivares PR, Greiner W. Can adult weights be used to value child health states? Testing the influence of perspective in valuing EQ-5D-Y. Qual Life Res. 2015;24:2519–39.CrossRefPubMedPubMedCentral
41.
go back to reference Oliva-Moreno J, Trapero-Bertran M, Peña-Longobardo LM, del Pozo-Rubio R. The valuation of informal care in cost-of-illness studies: a systematic review. PharmacoEconomics. 2017;35(3):331–45.CrossRefPubMed Oliva-Moreno J, Trapero-Bertran M, Peña-Longobardo LM, del Pozo-Rubio R. The valuation of informal care in cost-of-illness studies: a systematic review. PharmacoEconomics. 2017;35(3):331–45.CrossRefPubMed
42.
go back to reference Qian Y, McGraw S, Henne J, et al. Understanding the experiences and needs of individuals with spinal muscular atrophy and their parents: a qualitative study. BMC Neurol. 2015;15:217.CrossRefPubMedPubMedCentral Qian Y, McGraw S, Henne J, et al. Understanding the experiences and needs of individuals with spinal muscular atrophy and their parents: a qualitative study. BMC Neurol. 2015;15:217.CrossRefPubMedPubMedCentral
43.
44.
go back to reference Oliva J, Lopez-Bastida J, Montejo AL, Osuna R, Duque B. The socioeconomic costs of mental illness in Spain. Eur J Health Econ. 2009;10:361–9.CrossRef Oliva J, Lopez-Bastida J, Montejo AL, Osuna R, Duque B. The socioeconomic costs of mental illness in Spain. Eur J Health Econ. 2009;10:361–9.CrossRef
45.
go back to reference Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, De Vivo DC, Norris DA, Bennett CF, Bishop KM. Results from a phase 1 study of nusinerse (ISIS-SMN (Rx)) in children with spinal muscular atrophy. Neurology. 2016;86:890–7. doi: 10.1212PMC4782111CrossRefPubMedPubMedCentral Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, De Vivo DC, Norris DA, Bennett CF, Bishop KM. Results from a phase 1 study of nusinerse (ISIS-SMN (Rx)) in children with spinal muscular atrophy. Neurology. 2016;86:890–7. doi: 10.1212PMC4782111CrossRefPubMedPubMedCentral
46.
go back to reference Foust KD, Wang X, McGovern VL, Braun L, Bevan AK, Haidet AM, Le TT, Morales PR, Rich MM, Burghes AH, Kaspar BK. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol. 2010;28(3):271–4.CrossRefPubMedPubMedCentral Foust KD, Wang X, McGovern VL, Braun L, Bevan AK, Haidet AM, Le TT, Morales PR, Rich MM, Burghes AH, Kaspar BK. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol. 2010;28(3):271–4.CrossRefPubMedPubMedCentral
Metadata
Title
Social/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain
Authors
Julio López-Bastida
Luz María Peña-Longobardo
Isaac Aranda-Reneo
Eduardo Tizzano
Mark Sefton
Juan Oliva-Moreno
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2017
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-017-0695-0

Other articles of this Issue 1/2017

Orphanet Journal of Rare Diseases 1/2017 Go to the issue